Here's Why the Novavax CEO is Shrugging Off Moderna's and Pfizer's Market Dominance
You probably know at least one person who has struggled -- or is still struggling -- to get a coronavirus vaccine. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) began shipping their coronavirus vaccines around the United States late last year. But in many places, there are more individuals seeking vaccination than available doses.
President Joe Biden recently made a move that should solve the problem. He ordered enough Pfizer and Moderna vaccine to fully immunize nearly every American. That sounds like bad news for any other vaccine maker hoping to enter the U.S. market in the coming months. But Novavax (NASDAQ: NVAX) CEO Stanley Erck says that won't be a problem for the biotech company.
Image source: Getty Images.
Source Fool.com
